RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Announces $1.5 million Non-Brokered Private Placement
May 23, 2024 07:30 ET | Rakovina Therapeutics Inc
All monetary figures listed in Canadian Dollars. VANCOUVER, British Columbia, May 23, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company” or “Rakovina Therapeutics”) a...
Company logos
Rakovina Therapeutics Announces Extensions and Expansions of Strategic Collaborations to Support AI Research
May 08, 2024 08:00 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, May 08, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company” or “Rakovina Therapeutics”) a biopharmaceutical company committed to advancing new...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Inc. Announces 2023 Financial Results and Provides Corporate Update
April 26, 2024 20:38 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, April 26, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”) a biopharmaceutical company committed to advancing new cancer therapies based...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Presented at American Association of Cancer Research Annual Meeting at the San Diego Convention Center Today
April 09, 2024 16:05 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, April 09, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), (“Rakovina” or the “Company”), a biopharmaceutical company dedicated to improving the lives...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics To Host Informational Webinar on April 3, 2024
April 01, 2024 07:15 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, April 01, 2024 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), (“Rakovina Therapeutics” or the “Company”), a biopharmaceutical company dedicated to...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Announces Strategic Pivot to AI
March 27, 2024 16:05 ET | Rakovina Therapeutics Inc
Rakovina Therapeutics announces Artificial Intelligence (AI) collaboration
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Inc. Announces Q3 2023 Financial Results and Provides Corporate Update
November 27, 2023 19:43 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”), a biopharmaceutical company dedicated to improving the lives of cancer patients...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Welcomes Prof. Artem Cherkasov to the Company’s Scientific Advisory Board
November 27, 2023 09:00 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Nov. 27, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company focused on the development of novel DNA-damage...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Announces Appointment of New Scientific Advisory Board Member
November 20, 2023 09:13 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Nov. 20, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (“the Company”), a biopharmaceutical company focused on the development of novel DNA-damage...
RAKOVINA Logo Mar2021.png
Rakovina Therapeutics Inc. Announces Q2 2023 Financial Results and Provides Corporate Update
August 29, 2023 08:00 ET | Rakovina Therapeutics Inc
VANCOUVER, British Columbia, Aug. 29, 2023 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV, the “Company”), a biopharmaceutical company dedicated to improving the lives of cancer patients...